Press Release
Press Release
|
08-12
2024
|
Guangdong CJ pharmaceutical Co., Ltd was awarded the Excellent Team in the 12th “Chuangye Jiangsu” Science and Technological Entrepreneurship Competition (13th China Innovation and Entrepreneurship Competition Jiangsu Area). |
|
07-12
2024
|
The founder of Guangdong CJ pharmaceutical Co., Ltd, Dr. Zhang, won the first prize in Wuxi “Taihu Bei” International Innovation Competition (Xi’an area, China) with the topic of “Anticancer Drug Development of Nanotechnology”. |
|
11-16
2023
|
November 16th 2023, On November 16th 2023, Project 《Research development and application of new type ‘nanocrystal’ improvement for poorly water-soluble new drug》from Guangdong CJ pharmaceutical CO. performed excellent in semi-final and qualified for the final in the 3rd HENGQIN international and technological innovation and entrepreneurship competition. |
|
03-30
2023
|
March 30, 2023, GuangDong CJ Pharmaceutical Co. Ltd received around 10 million RMB Pre-A round of investment from a venture capital fund and several existing shareholders. The company will use this fund to develop the first nanocrystalline drug CJ-002, and initiate the Phase I clinical trail in the second half of the year. |
|
03-24
2023
|
March 24, 2023, GuangDong CJ Pharmaceutical Co. signed a cooperation agreement with Rundu Pharma (stock code: 002923) to scale up the GMP manufacturing for CJ-002, the first nanocrystalline drug. |
|
10-26
2022
|
October 26, 2022, GuangDong CJ Pharmaceutical Co. has advanced to the semifinals at 2022 Guangdong "Maker Cup" Entrepreneurship and Innovation Competition Technology Returnees Pilot Competition (Zhuhai region). |
| 08-30
2022
|
On August 30, 2022, GuangDong CJ Pharmaceutical Co. Ltd. completed an angel round financing of around 20 million RMB. The company introduced new shareholders of Shantou Zhendong Medical Technology Partnership (limited partnership), and the existing shareholders continued to increase their investments. The company will use this fund to develop nanocrystalline drugs and finish the "Nano-Solid DispersionTechnology Platform" project. |
| 06-16
2022
|
June 16, 2022, GuangDong CJ Pharmaceutical Co. Ltd has announced the initiation of bioequivalence (BE) clinical trail of the first product CJ-001 (CDE registration number: CTR20221381). |
| 12-31
2021
|
December 31, 2021, GuangDong CJ Pharmaceutical Co. won the Excellent prize at the 10th China Innovation and Entrepreneurship Competition (Guangdong region)，the 9th "the Pearl River Angel Cup" Science and Technology Innovation and Entrepreneurship Competition. |
| 11-29
2021
|
November 29, 2021, GuangDong CJ Pharmaceutical Co. won the 2021 Zhuhai Industry-University-Research Cooperation/Basic and Applied Research Projects, and signed a research cooperation with Macau University of Science and Technology. |
| 11-12
2021
|
November 12, 2021, GuangDong CJ Pharmaceutical Co. won the second prize at the 10th China Innovation and Entrepreneurship Competition (Guangdong Zhuhai region) and the 2021 Zhuhai Science and Technology Cup Innovation and Entrepreneurship Competition. Twenty-nine enterprises reached the finals, GuangDong CJ Pharmaceutical Co. ranked among the top two in 29 participants in Zhuhai city. |
| 07-23
2021
|
July 23, 2021, GuangDong CJ Pharmaceutical Co. Ltd has announced the initiation of pre-bioequivalence clinical trail of the first product CJ-001 in Qingyuan People's Hospital (CDE registration number: CTR20211728). |
| 11-31
2019
|
November 11, 2019, GuangDong CJ Pharmaceutical Co. Ltd signed several contracts with WuXi STA, a subsidiary of WuXi AppTec. Dr. Zhang, CEO of GuangDong CJ Pharmaceutical Co. Ltd, Dr. Chen, VP of WuXi STA, and other team members attended the cooperation signing ceremony at the headquarter of WuXi STA in Shanghai. Both companies will work together to develop medicines including CMC for drug approval and manufacturing for drug commercialization. WuXi STA is a leading pharmaceutical development and manufacturing capability and technology platform company serving the life sciences industry, with global operations. As a premier Contract Development and Manufacturing Organization (CDMO), WuXi STA offers worldwide partners efficient, flexible and high-quality solutions for integrated CMC (Chemical, Manufacturing, and Control) from preclinical to commercial. GuangDong CJ Pharmaceutical Co. Ltd. is an innovative pharmaceutical company for specialty drugs. The company is using special formulation technology to develop drugs in the fields of erectile dysfunction (ED), pulmonary artery hypertension (PAH), anticancer treatment and gout. The R&D pipelines include highly novel nanomedicines. |
| 08-02
2019 |
August 2, 2019, GuangDong CJ Pharmaceutical Co. Ltd received 20 million RMB Seed round of investment from several investors and venture capital fund. The company will use this fund to develop medicines in the fields of anti-cancer, goal, hyperuricemia and ED. |